3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
9
Leukemia
9
Hyperuricemia
9
Tumor Lysis Syndrome
7
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Lymphoma, Non-Hodgkin
3
Burkitt Lymphoma
3
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Hematologic Neoplasms
2
Congenital Abnormalities
2
Blast Crisis
2
Waldenstrom Macroglobulinemia
1
Sezary Syndrome
1
Recurrence
1
Primary Myelofibrosis
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Nutritional and Metabolic Diseases
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Immunoblastic
1
Lymphoma, Large-Cell, Anaplastic
1
Interventions
rasburicase
1
Urate Oxidase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Nutritional and Metabolic Diseases
×
rasburicase
×
Clear all
NCT00290992
2009-03-30
Rasburicase for Hyperuricemia
Sanofi
Phase 2
Completed
30 enrolled